Environmental

High R&D intensity supports a lower direct manufacturing footprint than peers with larger industrial operations, though outsourced supply chains still create upstream environmental exposure.

The company’s capital-light biotech model generally reduces energy, water, and waste burdens versus more asset-intensive healthcare peers, improving relative environmental positioning.

No material environmental controversies are indicated in the provided data, which supports a cleaner risk profile than peers facing plant, emissions, or remediation liabilities.

Environmental disclosure remains limited in the supplied metrics, so the score reflects a solid but not leading position relative to peers with more mature climate and resource reporting.

Social

Heavy R&D spending indicates sustained investment in scientific talent, which supports workforce quality and innovation culture relative to peers with lower research intensity.

Stock-based compensation at 8.4% of revenue suggests meaningful employee alignment, though it can dilute retention advantages versus peers with more balanced pay structures.

As a biotechnology company, patient and trial-participant safety, data integrity, and access ethics are material social factors, and no adverse signals are provided here.

The absence of reported labor or product-safety controversies in the supplied information supports a stronger social profile than peers with recurring compliance or conduct issues.

Governance

Net debt to EBITDA is negative, indicating conservative balance-sheet governance relative to leveraged peers and reducing creditor-driven oversight risk.

R&D at 33.1% of revenue shows disciplined reinvestment in the core pipeline, although it also heightens governance sensitivity around capital allocation and trial oversight.

Stock-based compensation remains moderate for a growth biotech, suggesting compensation governance is acceptable versus peers but not clearly best-in-class.

The provided metrics do not show severe leverage or compensation red flags, so governance appears stronger than average but short of top-tier peer leadership.

Overall Score

ALNY’s ESG positioning is stronger than many biotech peers because its capital-light model, high R&D focus, and conservative leverage reduce several material ESG risks.

Score Driver: Conservative Balance-Sheet Structure Combined With A Capital-Light Biotech Operating Model